A fluorescence-based sensor screen identifies MED12 as a potential microsatellite instability regulator in colon cancer
Fernandes Neto, J. M.; Venkatesan, S.; Dias, M.; Lieftink, C.; Morris, B.; Bresser, K.; Vecchione, L.; Evers, B.; Scheeren, F.; Shumacher, T.; Beijersbergen, R.; Bernards, R.
Show abstract
Inactivation of the DNA mismatch repair (MMR) system, due to (epi)genetic alterations of MMR genes, increases the frequency of mutations across the genome, creating a phenotype known as microsatellite instability (MSI). Cancers with this phenotype have been associated with a better prognosis for some time, but only since recently it has been recognised as a predictive biomarker of response to immunotherapy. Because MSI tumours accumulate more insertions and/or deletions in coding regions of the genome containing microsatellites, there is an increase in neoantigens resulting from reading frame shifts, which promotes immunogenicity. To investigate if additional genes exist that can cause an MSI phenotype, we developed a fluorescence-based sensor to identify genes whose inactivation increases the rate of frameshift mutations on microsatellite sequences in cancer cells. Using genome-scale CRISPR/Cas9 screens, we identified MED12 as a potential new regulator of microsatellite instability. Consistent with this, we found that MED12 mutant colon cancers that lack mutations in the known MMR genes are more likely to be of the MSI phenotype.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.